Saturday, November 23, 2024
HomeTagsChiesi Global

Chiesi Global

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry...

Protalix BioTherapeutics, Inc. a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell‑based...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics